Market Size of Global HPV Testing and Pap Test Industry
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 6.21 Billion |
| Market Size (2029) | USD 10.33 Billion |
| CAGR (2024 - 2029) | 10.70 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
HPV Testing and PAP Test Market Analysis
The Global HPV Testing and Pap Test Market size is estimated at USD 6.21 billion in 2024, and is expected to reach USD 10.33 billion by 2029, growing at a CAGR of 10.70% during the forecast period (2024-2029).
The COVID-19 pandemic had a significant impact on the market. Many countries were in lockdown and suspended trade with other countries, leading to a decline in healthcare services, including the diagnosis of various diseases. In 2020, with the rising COVID-19 pandemic globally, various elective medical procedures, including cancer screening, were found to be largely put on hold to prioritize other urgent needs and reduce the risk of the spread of COVID-19. This has shown a substantial decline in cancer screening. However, cancer care and maintaining high standards of diagnosis and treatment have been the major priorities of the national healthcare bodies and international healthcare systems worldwide.
The driving factors of the market are the increasing number of cervical cancer cases across the globe, an increasing number of cervical cancer screening programs, and the introduction of advanced technologies.
According to the World Health Organization (WHO), in 2020, more than half a million women contracted cervical cancer, and about 342,000 women died as a result. WHO's global strategy for cervical cancer elimination, endorsed by the World Health Assembly in 2020, calls for 70% of women globally to be screened regularly for cervical disease with a high-performance test, and for 90% of those needing it to receive appropriate treatment, that may
Additionally, according to the American Cancer Society 2022 estimates about 14,110 new cases of invasive cervical cancer were diagnosed in the United States. Thus, globally, the increasing number of cervical cancer cases may increase the demand for HPV testing and PAP tests, driving the growth of the market.
The growing number of cervical cancer cases increases the demand for screening programs. The tests are found to address deficiencies in traditional cervical screening that has led to alternative screening paradigms such as those involving detection of the human papillomavirus (HPV). Companies like Qiagen NV are having technologically advanced tests that detect HPV DNA such as Capture 2 test, which detects the presence of 13 high-risk HPV types in the cervical sample. Hence, all these factors have impacted the overall market growth.
